ST6GAL1 and colorectal carcinoma: Here, we discovered that high expression of ST6GAL1 in CRC cells might drive the activation of EGFR‐related pathways, offering new insights for selecting CRC patients suitable for cetuximab therapy (anti‐EGFR).